An Open Label Phase I Study to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Based Vaccine Modified to Express Brachyury and T-Cell Costimulatory Molecules (MVA Brachyury-TRICOM)
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2018
Price : $35 *
At a glance
- Drugs MVA brachyury TRICOM vaccine (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 07 Apr 2017 Status changed from active, no longer recruiting to completed.
- 02 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.